Posted by Michael Wonder on 23 Nov 2017
Roche’s Erivedge no longer funded by the NHS
23 November 2017 - Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective.
Erivedge (vismodegib) was made available to patients with advanced basal cell carcinoma unable to receive surgery or radiotherapy via the old CDF in 2013.
But following a reappraisal, NICE’s committee concluded that its clinical benefit was unclear.
